Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Differentiated Thyroid Cancer 2Colorectal Neoplasms 2Stomach Neoplasms 1Solid Tumor 1Nasopharyngeal Carcinoma 1Leukemia, Myeloid, Acute 1Esophageal Neoplasms 1Advanced Solid Tumor 1

Interventions

Thyrotropin Alfa 4donafenib 2Injections 2vandetanib 1anlotinib 1Iodine-131 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Differentiated Thyroid Cancer × donafenib × Clear all
NCT03602495 2021-12-13

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Terminated
204 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT02870569 2019-03-01

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Completed
48 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡